View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
April 29, 2020

Coronavirus company news summary – Outer Reef Technologies introduces open source ventilator – ACAMP in Canada develops reusable respirators

By Chloe Kent

29 April

Non-profit Canadian organisation ACAMP has developed a reusable respirator with the guidance of University of Alberta researchers to aid in the fight against Covid-19. The filters in the respirator can be washed and reused again. A team at Engineering at Alberta tested the effectiveness of the filter against the N95-rated respirators. As per the results, the ACAMP A95 filters offer the same level of filtration efficiency as the N95 filters which are commercially available.

Outer Reef Technologies has developed an open source ventilator that has the same functionality and modes of other ventilators that are approved by the FDA. The ‘Omnis’ ventilator design includes Assist Control Volume/Pressure Ventilation and CPAP. The company stated that the ventilator can be assembled using six readily available components within one hour at a cost of only $500 in parts. The step-by-step instructions, materials list, videos, mobile patient monitoring app and supporting firmware are available on the company’s website.

SeaStar Medical has received Investigational Device Exemption (IDE) supplement from the US Food and Drug Administration (FDA) to start a feasibility study. The Selective Cytopheretic Device (SCD), which is an immunomodulating medical device, will target patients who tested positive for Covid-19 and have acute respiratory distress syndrome (ARDS) or Acute Kidney Injury (AKI).

BIOTECON Diagnostics announced that it has developed and launched a microproof SARS-CoV-2 Screening/Identification Kit. The kit can be bought and distributed around the world, the company has said. The microproof SARS-CoV-2 Screening/Identification Kits received the approval ‘for research use only’ (RUO) and are pending CE-IVD and the Emergency Use Authorization (EUA) from the FDA. The assays were developed using the reference methods of the WHO, adapted based on the protocol of Charité (Berlin, Germany) to the detect the presence of SARS-CoV-2.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network